FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Seeking Alpha

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

East Hanover, N.J., Aug. 7, 2024 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class ...
Yahoo Finance

Achillion Begins Study on First Complement Factor D Inhibitor

Achillion Pharmaceuticals, Inc. ACHN announced that it has started a phase I study on its first orally administered small molecule complement factor D inhibitor, ACH-4471. The randomized, ...
manilatimes

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement ...

SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Business Insider

Novartis Receives FDA Accelerated Approval For Fabhalta As First Complement Inhibitor For IgAN

(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of ...
Business Insider

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for ...

SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Business Wire

First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and targeted cancers in ...
Nature

Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes

To investigate levels of components of the alternative pathway of complement, and of two activation products, ASP and Bb, in persons ranging in insulin resistance both fasting and following the ...
adexchanger

Goodway Group Stitches Together Identity Graph To Complement Brands’ First-Party Data

With new first-party ID solutions flooding the market, the buy side of the ad industry is looking for ways to enhance campaign targeting and attribution by matching different first-party data sets. To ...